Trial · NCT07228624
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
NCT07228624, Phase 2, Recruiting, Fred Hutchinson Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes. Trials, record NCT07228624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07228624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
- NCT number
- NCT07228624
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Fred Hutchinson Cancer Center
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- First posted
- 2025-11-14
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of grade II-IV graft versus host disease (GVHD) requiring systemic immune suppression | Up to day-100 | Will be estimated as a simple proportion, and the upper bound of the one-sided 95% confidence interval for the estimated proportion will be estimated using the Clopper-Pearson method. The exact binomial test will be used to compare the observed probability to the benchmark of 65%. |
| Secondary | Incidence of grade III-IV acute GVHD | Up to day-100 | Will be estimated as simple proportions and informally compared to the results from the historical cohort. |
| Secondary | Incidence of any-grade chronic GVHD | Up to 1 and 2 years | Will be treated as time-to-event endpoints, with specified point estimates. |
| Secondary | Incidence of moderate-to-severe chronic GVHD | Up to 1 and 2 years | Will be treated as time-to-event endpoints, with specified point estimates. |
| Secondary | Non-relapse mortality (NRM) | At day-100 | Will be estimated as simple proportions and informally compared to the results from the historical cohort. |
| Secondary | NRM | At 1 year | Will be treated as time-to-event endpoints, with specified point estimates. |
| Secondary | Remission status | At day-100 | Will be estimated as simple proportions and informally compared to the results from the historical cohort. |
| Secondary | Relapse rate | At 1 and 2 years | Will be treated as time-to-event endpoints, with specified point estimates. |
| Secondary | Overall survival | Up to 1 year and by end of study, assessed up to 2 years | Will be treated as time-to-event endpoints, with specified point estimates. |
| Secondary | Incidence of graft failure | Up to day-100 | Will be estimated as simple proportions and informally compared to the results from the historical cohort. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07228624
GET https://conductscience.org/api/trials/v1/NCT07228624/registered